Blood 'Cleansing' may revive bladder cancer treatment
NCT ID NCT07087860
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a procedure that filters a patient's blood (therapeutic plasma exchange) can help standard cancer drugs work better in people with advanced bladder or urinary tract cancer that has stopped responding to previous treatments. About 70 adults will be randomly assigned to receive either the blood-filtering procedure plus two approved drugs (enfortumab vedotin and pembrolizumab) or the usual next-line therapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for advanced bladder cancer? bevacizumab combo tested
- Bladder cancer breakthrough? trial tests stopping immunotherapy early
- New hope for advanced bladder cancer? drug targets specific gene mutations
- Scientists hunt for clues to cancer drug resistance in tissue samples
- New combo aims to fight tough bladder cancer
- Immunotherapy-Chemo combo targets tough neuroendocrine cancers